KOBO BIOTECH LTD.

NSE : NABSE : 531541ISIN CODE : INE881A01015Industry : Pharmaceuticals & DrugsHouse : Private
BSE4.090 (0 %)
PREV CLOSE ( ) 4.09
OPEN PRICE ( ) 4.08
BID PRICE (QTY) 3.91 (804)
OFFER PRICE (QTY) 4.09 (7010)
VOLUME 10129
TODAY'S LOW / HIGH ( )3.89 4.09
52 WK LOW / HIGH ( ) 2.046.01
NSE
This Company is not listed in NSE
( in Million)
Select year
ParticularsMar2014Mar2013Mar2012Mar2011
Profit Before Tax-342.72148.72176.71NA
Adjustment335.97283.72314.40NA
Changes In working Capital79.36-47.35167.75NA
Cash Flow after changes in Working Capital72.61385.09658.86NA
Cash Flow from Operating Activities67.17367.23638.90NA
Cash Flow from Investing Activities-47.05-69.91-144.32NA
Cash Flow from Financing Activities-128.48-383.89-268.19NA
Net Cash Inflow / Outflow-108.36-86.56226.39NA
Opening Cash & Cash Equivalents164.77251.3324.94NA
Cash & Cash Equivalent on Amalgamation / Take over / MergerNANANANA
Cash & Cash Equivalent of Subsidiaries under liquidationsNANANANA
Translation adjustment on reserves / op cash balalces frgn subsidiariesNANANANA
Effect of Foreign Exchange FluctuationsNANANANA
Closing Cash & Cash Equivalent56.41164.77251.33NA

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.